- Exchange: NASDAQ CM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Keryx Biopharmaceuticals Inc+ Add to Watchlist
KERX:US15.1500 USD 0.2900 1.95%
As of 20:10:00 ET on 07/25/2014.
Company Profile for Keryx Biopharmaceuticals Inc (KERX)
Keryx Biopharmaceuticals, Inc. is focused on developing and commercializing pharmaceuticals for the treatment of renal disease. The Company's product candidate completed Phase 3 testing, pursuant to an SPA agreement with the FDA, for hyperphosphatemia in ESRD patients. The product candidate is also in Phase 2 for non-dialysis dependent CKD patients with iron-deficiency anemia.
Keryx Biopharmaceuticals Inc
Key Executives for Keryx Biopharmaceuticals Inc (KERX)
|Ron BentsurChief Executive Officer||James F OlivieroCFO/Treasurer/Secretary|
|Gregory P Madison "Greg"Exec VP/COO||Brian R AdamsVP/General Counsel|
|Amy B SullivanVP:Corporate Dev & Public Affairs||Thomas M EdwardsVP:US Sales|
|Lauren FischerDirector:Investor Relations|